Vagal nerve stimulation during muscarinic and beta-adrenergic blockade causes significant coronary artery dilation

Journal of the Autonomic Nervous System

Volumn 68, Issue 1-2, 1998, Pages 78-88

  Feliciano, Lillybeth ^a   Henning, Robert J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

A V nodal block; Coronary artery pressure; Coronary vascular resistance; Mongrel dog; Noneholinergic nonadrenergic nerve stimulation; Vasoactive intestinal peptide

Indexed keywords

ADRENERGIC NERVE; ANIMAL EXPERIMENT; ARTICLE; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY VASCULAR RESISTANCE; DOG; HEART LEFT VENTRICLE DP-DT; NONHUMAN; PRIORITY JOURNAL; SYMPATHETIC INNERVATION; VAGUS NERVE;

EID: 0032545628     PISSN: 01651838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1838(97)00109-4     Document Type: Article

References (45)

1. Accili E.A., Buchan A.M.J., Kwok Y.N., Ledsome J.R., Brown J.C. Presence and actions of vasoactive intestinal peptide in the isolated rabbit heart. Can. J. Physiol. Pharmacol. 73(1):1995;134-139.
2. Anderson F.L., Kralios A.C., Cluff N., Hanson G.R. Vagal-induced tachycardia: Release of vasoactive intestinal peptide and peptide HI. Am. J. Physiol. 267:1994;H2019-H2024.
3. Anderson F.L., Kralios A.C., Hershberger R., Bristow M.R. Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: Comparison with isoproterenol and forskolin. J. Cardiovasc. Pharmacol. 12(3):1988;365-371.
4. Anderson F.L., Kralios A.C., Reid B., Hanson G.R. Release of vasoactive intestinal peptide and neuropeptide Y from canine heart. Am. J. Physiol. 265:1993;H959-H965.
5. Anderson F.L., Wynn J.R., Kimball J., Hanson G.R., Hammond E., Hershberger R., Kralios A.C. Vasoactive intestinal peptide in canine hearts: Effect of total cardiac denervation. Am. J. Physiol. 262:1992;H598-H602.
6. B.M. Bennet, S.A. Waldman, Cyclic nucleotides and protein phosphorylation in vascular smooth muscle relaxation, in: N. Sperelakis (Ed.), Physiology and Pathophysiology of the Heart, Kluwer Academic publishers, Norwell, Massachusetts, 1995, pp. 975-998.
7. Beny J.L., Brunet H., Huggel H. Effect of mechanical stimulation, substance P and vasoactive intestinal polypeptide on the electrical and mechanical activities of circular smooth muscles from pig coronary arteries contracted with acetylcholine: Role of endothelium. Pharmacology. 33(2):1986;61-68.
8. Brum J.M., Bove A.A., Sufan Q., Reilly W., Go Vay L.W. Action and localization of vasoactive intestinal peptide in the coronary circulation: Evidence for nonadrenergic, noncholinergic coronary regulation. J. Am. Coll. Cardiol. 7(20):1986;406-413.
9. Christophe J., Waelbroeck M., Chatelain P., Robberecht P. Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology. Peptides. 5(2):1984;341-353.
10. Della N.G., Papka R.E., Furness J.B., Costa M. Vasoactive intestinal peptide-like immunoreactivity in nerves associated with the cardiovascular system of guinea-pigs. Neuroscience. 9(3):1983;605-619.
11. Fahrenkrug J., Ottesen B. Nervous release of vasoactive intestinal polypeptide from the feline uterus: Pharmacological characteristics. J. Physiol. 331:1982;451-460.
12. Forssman W.G., Triepel J., Daffner C., Heym C.H., Cuevas P., Noble M.I., Yanaihara N. Vasoactive intestinal peptide in the heart. Ann. N. Y. Acad. Sci. 527:1988;405-420.
13. Ganz P., Sandrock A.W., Landis S.C., Leopold J., Gimbrone M.A., Alexander R.W. Vasoactive intestinal peptide: Vasodilation and cyclic AMP generation. Am. J. Physiol. 250:1986;H755-H760.
14. Grider J.R., Rivier J. Vasoactive intestinal peptide (VIP) as transmitter of inhibitory motor neurons of the gut: Evidence from the use of selective VIP antagonists and VIP antiserum. J. Pharmacol. Exp. Ther. 253(2):1990;738-742.
15. 17)VIP. Pfluegers Arch. 414(2):1989;222-227.
16. Gulbenkian S., Opgaard O.S., Ekman R., Costa N., Wharton J., Polak J., Melo J., Edvinsson L. Peptidergic innervation of human epicardial coronary arteries. Circ. Res. 73(3):1993;579-588.
17. Heistad D.D., Marcus M.L., Said S.I., Gross P.M. Effects of acetylcholine and vasoactive intestinal polypeptide on cerebral blood flow. Am. J. Physiol. 239(1):1980;H73-H80.
18. Henning R.J. Vagal stimulation during muscarinic and beta-adrenergic blockade increases atrial contractility and heart rate. J. Auton. Nerv. Syst. 40(2):1992;121-129.
19. Henning R.J., Feliciano L., Coers C.M. Vagal nerve stimulation increases right ventricular contraction and relaxation and heart rate. Cardiovas. Res. 32(5):1996;846-853.
20. Hill M.R.S., Wallick D.W., Martin P.J., Levy M.N. Effects of repetitive vagal stimulation on heart rate and on cardiac vasoactive polypeptide efflux. Am. J. Physiol. 26:1995;H1939-H1946.
21. Hoover D.B. Effects of guinea pig vasoactive intestinal peptide on the isolated perfused guinea pig heart. Peptides. 10(2):1989;343-347.
22. Huang M., Rorstad O.P. VIP receptors in mesenteric and coronary arteries: A radioligand binding study. Peptides. 8(3):1987;477-485.
23. Itoh H., Lederis K.P., Rorstad O.P. Relaxation of isolated bovine coronary arteries by vasoactive intestinal peptide. Eur. J. Pharmacol. 181(3):1990;199-205.
24. Katz A.M. Interplay between inotropic and lusitropic effects of cyclic adenosine monophosphate on the myocardial cell. Circulation. 82:1990;I7-I11.
25. Kelley K.O., Feigl E.O. Segmental alpha-receptor-mediated vasoconstriction in the canine coronary circulation. Circ. Res. 43(6):1978;908-917.
26. Kobayashi H., Uezono Y., Ueno S., Izumi F. Pituitary adenylate cyclase-activating polypeptides (PACAPs) increase cAMP in rat cerebral microvessels. Brain Res. 647(1):1994;145-147.
27. Lundberg J.M. Evidence for coexistence of vasoactive intestinal peptide (VIP) and acetylcholine in neurons of cat exocrine glands: Morphological, biochemical and functional studies. Acta Physiol. Scand. 496:1981;1-57.
28. Lundberg J.M., Anggard A., Fahrenkrug J. Complementary role of vasoactive intestinal polypeptide (VIP) and acetylcholine for cat submandibular gland blood flow and secretion. I. VIP release. Acta Physiol. Scand. 113(3):1981;317-327.
29. Lundberg J.M., Franco-Cereceda A., Lacroix J.S., Pernow J. Release of vasoactive peptides from autonomic and sensory nerves. Blood Vessels. 28:1991;27-34.
30. Lundberg J.M., Hökfelt T. Multiple co-existence of peptides and classical transmitters in peripheral autonomic and sensory neurons: Functional and pharmacological implications. Prog. Brain Res. 68:1986;241-262.
31. Morgan J.P., Perreault C.L., Morgan K.G. The cellular basis of contraction and relaxation in cardiac and vascular smooth muscle. Am. Heart J. 121:1991;961-968.
32. Nilsson S.F.E., Bill A. Vasoactive intestinal polypeptide (VIP): Effects in the eye and on regional blood flows. Acta Physiol. Scand. 121(4):1984;385-392.
33. 17]VIP. Am. J. Physiol. 250:1986;G553-G557.
34. Popma J.J., Smitherman T.C., Bedotto J.B., Eichhorn E.J., Said S.I., Dehmer G.J. Direct coronary vasodilation induced by intracoronary vasoactive intestinal peptide. J. Cardiovasc. Pharmacol. 16(6):1990;1000-1006.
35. 17]VIP in the awake dog. Peptides. 12(5):1991;989-993.
36. Scheel K.W., Ingram L.A., Gordey R.L. Relationship of coronary flow and perfusion territory in dogs. Am. J. Physiol. 243(5):1982;H738-H747.
37. Shvilkin A., Danilo P., Chevalier P., Chang F., Cohen I.S., Rosen M. Vagal release of vasoactive intestinal peptide can promote vagotonic tachycardia in the isolated innervated rat heart. Cardiovas. Res. 28:1994;1769-1773.
38. Smitherman T.C., Popma J.J., Said S.I., Krejs G.J., Dehmer G.J. Coronary hemodynamic effects of intravenous vasoactive intestinal peptide in humans. Am. J. Physiol. 257:1989;H1254-1262.
39. Sperelakis N., Xiong Z., Haddad G., Masuda H. Regulation of slow calcium channels of myocardial cells and vascular smooth muscle cells by cyclic nucleotides and phosphorylation. Mol. Cell. Biochem. 140(2):1994;103-117.
40. Steiner C., Kovalik A.T. A simple technique for production of chronic complete heart block in dogs. J. Appl. Physiol. 25(5):1968;631-632.
41. Unverferth D.V., O'Dorisio T.M., Muir W.W., White J., Miller M.M., Hamlin R.L., Magorien R.D. Effect of vasoactive intestinal polypeptide on the cardiovascular system. J. Lab. Clin. Med. 106(5):1985;542-550.
42. Weihe E., Reinecke M. Peptidergic innervation of the mammalian sinus nodes: Vasoactive intestinal polypeptide, neurotensin, substance P. Neurosci. Lett. 26(3):1981;283-288.
43. Weihe E., Reinecke M., Forssman W.G. Distribution of vasoactive intestinal polypeptide-like immunoreactivity in the mammalian heart. Interrelation with neurotensin- and substance P-like immunoreactive nerves. Cell Tissue Res. 236(3):1984;527-540.
44. Wharton J., Gulbenkian S. Peptides in the mammalian cardiovascular system. Experientia. 56:1989;292-316.
45. Xenopoulos N.P., Applegate R.J. Effects of vasoactive intestinal peptide on myocardial performance. Am. J. Physiol. 266:1994;H399-H405.